As of 2026-11-07, the Intrinsic Value of GPX Medical AB (GPXMED.ST) is 1.25 SEK. This GPXMED.ST valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 2.67 SEK, the upside of GPX Medical AB is -53.30%.
The range of the Intrinsic Value is (0.21) - 4.07 SEK
Based on its market price of 2.67 SEK and our intrinsic valuation, GPX Medical AB (GPXMED.ST) is overvalued by 53.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (560.74) - (40.23) | (74.20) | -2879.0% |
| DCF (Growth 10y) | (58.06) - (789.17) | (105.89) | -4066.0% |
| DCF (EBITDA 5y) | (0.21) - 4.07 | 1.25 | -53.3% |
| DCF (EBITDA 10y) | (2.38) - 8.30 | 1.14 | -57.2% |
| Fair Value | -1.58 - -1.58 | -1.58 | -159.16% |
| P/E | (5.91) - (7.82) | (7.28) | -372.7% |
| EV/EBITDA | (1.85) - 1.98 | (0.41) | -115.5% |
| EPV | 3.10 - 4.00 | 3.55 | 33.1% |
| DDM - Stable | (3.63) - (29.01) | (16.32) | -711.2% |
| DDM - Multi | (7.17) - (47.20) | (12.70) | -575.8% |
| Market Cap (mil) | 56.20 |
| Beta | 0.99 |
| Outstanding shares (mil) | 21.05 |
| Enterprise Value (mil) | 37.45 |
| Market risk premium | 4.74% |
| Cost of Equity | 7.34% |
| Cost of Debt | 5.00% |
| WACC | 5.63% |